Vulvovaginal Candidiasis Treatment Market Size, Growth, Trends | Report 2022-2030
Vulvovaginal Candidiasis (VVC) is one of the most common infections among women, affecting around 138 million women annually worldwide. Globally, vulvovaginal candidiasis affects about 75% of women, with at least one incidence over a lifetime. It is estimated that approximately 10%-20% of women suffer from complicated VVC. In addition, recurrent VVC prevalence is rising, affecting more than 9% of women annually. In recent years, VVC prevalence has increased due to growing diabetes cases and repeated antibiotic usage among individuals. About 15% of women in all these cases require special therapeutic considerations. All these factors raise the demand for effective therapeutics, thereby creating lucrative opportunities for market players.
Global players are strategically addressing the market need by engaging in the R&D of new drugs and product launches. For instance, in August 2022, Mycovia Pharmaceuticals’ received FDA approval for VIVJOA (Oral small-molecule selective fungal CYP51 inhibitor) in the U.S. It is the first approved drug for treating recurrent VVC in females, before the U.S. this drug was already approved in some European, Asian, Latin American countries. Furthermore, emerging novel drug therapies are expected to boost treatment options. For instance, in June 2021, FDA approved, Scynexis, Inc.’s Brexafemme (Ibrexafungerp), a novel drug class used to treat vulvovaginal candidiasis. The subsequent launch of these drugs over the coming years is expected to accelerate market growth.
In the market, the route of administration segment has been sub-segmented as:
The space has a substantial presence of over-the-counter intravaginal agents for treating mild to moderate conditions. This includes products such as clotrimazole cream, miconazole cream, and tioconazole ointment. These products are recommended as first-line therapies for the disease indication. In addition, the demand for prescription products is also rising due to growing moderate to severe disease cases; some of the popular prescription products include butoconazole cream, terconazole cream, and fluconazole oral drugs. Long-duration therapy of oral fluconazole is recommended for initial therapy and maintenance regime for complicated VVC. Other treatment options include Echinocandins (caspofungin, micafungin) and amphotericin B deoxycholate, administered through IV and infusion.
The recent advancement in vulvovaginal candidiasis space, such as immunopathology, inflammasome, the role of candidalysin, and PRR-mediated signaling at the vaginal mucosa, have opened multiple opportunities for new drug development and treatment options.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Vulvovaginal Candidiasis Treatment Market
5.1. COVID-19 Landscape: Vulvovaginal Candidiasis Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Vulvovaginal Candidiasis Treatment Market, By Drug class
8.1. Vulvovaginal Candidiasis Treatment Market, by Drug class, 2022-2030
8.1.1 Clotrimazole
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Nystatin
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Fluconazole
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Ketoconazole
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Terbinafine
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Terconazole
8.1.6.1. Market Revenue and Forecast (2017-2030)
8.1.7. Others
8.1.7.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Vulvovaginal Candidiasis Treatment Market, By Route of administration
9.1. Vulvovaginal Candidiasis Treatment Market, by Route of administration, 2022-2030
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Intravenous
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Topical
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Vulvovaginal Candidiasis Treatment Market, By Distribution channel
10.1. Vulvovaginal Candidiasis Treatment Market, by Distribution channel, 2022-2030
10.1.1. Hospital Pharmacy
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Retail Pharmacy
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Online Pharmacy
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Vulvovaginal Candidiasis Treatment Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug class (2017-2030)
11.1.2. Market Revenue and Forecast, by Route of administration (2017-2030)
11.1.3. Market Revenue and Forecast, by Distribution channel (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug class (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Route of administration (2017-2030)
11.1.4.3. Market Revenue and Forecast, by Distribution channel (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug class (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Route of administration (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Distribution channel (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug class (2017-2030)
11.2.2. Market Revenue and Forecast, by Route of administration (2017-2030)
11.2.3. Market Revenue and Forecast, by Distribution channel (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug class (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Route of administration (2017-2030)
11.2.4.3. Market Revenue and Forecast, by Distribution channel (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug class (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Route of administration (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Distribution channel (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug class (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Route of administration (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Distribution channel (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug class (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Route of administration (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Distribution channel (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug class (2017-2030)
11.3.2. Market Revenue and Forecast, by Route of administration (2017-2030)
11.3.3. Market Revenue and Forecast, by Distribution channel (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug class (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Route of administration (2017-2030)
11.3.4.3. Market Revenue and Forecast, by Distribution channel (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug class (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Route of administration (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Distribution channel (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug class (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Route of administration (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Distribution channel (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug class (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Route of administration (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Distribution channel (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug class (2017-2030)
11.4.2. Market Revenue and Forecast, by Route of administration (2017-2030)
11.4.3. Market Revenue and Forecast, by Distribution channel (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug class (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Route of administration (2017-2030)
11.4.4.3. Market Revenue and Forecast, by Distribution channel (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug class (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Route of administration (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Distribution channel (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug class (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Route of administration (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Distribution channel (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug class (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Route of administration (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Distribution channel (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug class (2017-2030)
11.5.2. Market Revenue and Forecast, by Route of administration (2017-2030)
11.5.3. Market Revenue and Forecast, by Distribution channel (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug class (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Route of administration (2017-2030)
11.5.4.3. Market Revenue and Forecast, by Distribution channel (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug class (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Route of administration (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Distribution channel (2017-2030)
Chapter 12. Company Profiles
12.1. Astellas Pharma Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Mycovia Pharmaceuticals, Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Basilea Pharmaceutica Ltd.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Scynexis, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Grupo Ferrer Internacional, S.A.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Pfizer, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers